Cohance Lifesciences Limited and Suven Pharmaceuticals Limited have recently announced their merger, bringing together complementary strengths to form a larger and more versatile Contract Development and Manufacturing Organization (CDMO). This announcement followed the final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. Effective from May 1, 2025, and in accordance with the terms of the approved Scheme of Amalgamation, the merged entity will operate under the name – “Cohance Lifesciences Limited”.
This move aims to expand their global presence, broaden their service platform, and offer more value to the pharmaceutical and biotech industry. Cohance Lifesciences Limited will combine Suven’s scale and commercial execution capabilities with Cohance’s expertise in ADC, oligonucleotides, and complex chemistry platforms, to accelerate innovation and enhance execution across the value chain. The merger is also expected to create new opportunities by combining both companies’ customer networks, chemical expertise, and manufacturing capacity. Post-merger, Cohance Lifesciences has initiated operational and organizational integration to align systems, capabilities, and teams.
To read the full press release, visit https://www.suvenpharm.com/pdf/Investors/ShareHoldersInfo/Stock%20Exchange%20Communications/SuvenPharma_PressRelease25042025.pdf